MD MEDICAL GROUP OPENS NEW SURGERY CENTRE «LAPINO-2»

17 September, Moscow – MD Medical Group Investments Plc («MD Medical Group», «MDMG» or the «Company» – LSE: MDMG), a leading Russian private healthcare provider, announces that it has inaugurated the new surgery centre «Lapino-2» – the second stage of the multi-disciplinary hospital Lapino.

The hospital’s construction began on 30 May 2018. The Group’s total investment in the project amounted to 3.9 billion roubles. The “Lapino-2” hospital is one of the largest projects in the healthcare sector conmmisioned in the recent period in Russia.

The new 6-storey surgery building with an area of 18,500 sq m will provide medical services for all family members, including those under the MHI program. “Lapino-2” is to carry out 12,000 operations, about 40,000 in-patient days and more than 180,000 out-patient treatments per year. A multi-level parking facility in a separate building for 277 cars was built near the hospital for the convenience of patients (CAPEX 300 million rubles).

“Lapino-2” includes departments for cardiovascular surgery, stomatology, including oral and maxillofacial surgery, a diagnostical department, a hemodialysis department, an intensive care unit with 13 beds, 6 operating theatres for planned surgeries and 2 for emergency surgeries.

“Lapino-2” houses a state-of-the-art oncology centre that offers a full cycle medical service on a high level with adherence to modern world protocoles – from screening and diagnosis verification to high-tech oncosurgical care, chemoradiotherapy and oncological rehabilitation.

The new oncocentre includes departments with the following specialization: oncohematology, chemotherapy, general oncology, thoracoabdominal oncology, coloproctology, oncogynaecology, oncourology, head and neck tumors. The chemotherapy department that opened at the Lapino hospital in the beginning of 2020 will be significantly expanded. The oncology centre will provide 18,000 cycles of chemotherapy, including immunotherapy and targeted therapy, as well as neoadjuvant therapy year-on-year. Medical service will be provided on a commercial basis and under the VHI and MHI programs. For this purpose a team of leading Russian oncologists has joined the Company.

The hospital will also operate a state-of-the-art microbiological laboratory offering a full range of diagnostic testing, in particular with time-of-flight mass metering, flow cytometry for examining the patient's immune status, as well as an infectious serology unit. The PCR laboratory will conduct studies to analyze the impact of various pathogens of viruses (including COVID-19), which will help to test various vaccines.

“Lapino-2” will operate in accordance with the Company’s customary high standard of medical care. The surgery building has world-class equipment produced by GE Healthcare, Philips, Siemens, Olympus, Origio, Draeger, Lumenis, Getinge, Maquet. The dental department is equipped by KAVO, Sirona, Renfer, Wasserman, SAM, EMS, as well as Matrix Parker Hannifin Corporation. PCR equipment produced by Bio-Rad, Elmi, Eppendorf was installed in the new laboratory.

Mark Kurtser, CEO of MD Medical Group, said:

“The launch of the “Lapino-2” surgery centre constitutes an important step in the development of the Company. The Lapino hospital has been operating successfully for many years and acquired in the course of time the confidence and gratitude of thousands of patients. Today it rises to a new level in providing planned and emergency medical help. Launching this large scale centre and new departments, Lapino is becoming a major multifunctional medical centre which provides 24/7 medical help to patients with various problems”.